University of Maribor, Faculty of Health Sciences
Maribor, 2000, Slovenia
Location status: Recruiting
NCT Number: NCT06755307
The goal of this randomized controlled clinical trial is to determine the effect of the probiotic OMNiBiOTiC® Panda in treating diaper dermatitis in children under the age of two years. The main question it aims to answer is:
Is the probiotic OMNiBiOTiC® Panda effective in reducing the duration of diaper dermatitis in children under the age of two years?
Researchers will compare the probiotic and placebo group to see if the duration of diaper dermatitis is significant among the two groups.
Participants will:
* receive 6 droplets daily of probiotic or placebo for 3 weeks and * observe and record improvement of diaper rash symptoms each day using a diary.
Interested in participating?
Request Info1 month–2 year
All sexes
Interventional
Not applicable
Maribor, 2000, Slovenia
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Multistrain Probiotic OMNiBiOTiC® Panda containing: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactococcus lactis W58 and sunflower oil
Placebo containing sunflower oil and maltodextrin
Time frame: 3 weeks supplementation
Comparison of the duration of diaper dermatitis in children younger than two years in both arms via daily the use of the diary.
University Maribor
Other
PROBIOTICS FOR TREATING DIAPER DERMATITIS IN CHILDREN - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
Acronym: ProDiaper II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07633808
Dermatitis, Dermatitis, Contact
Tulkarm, Palestinian Territories
View Trial DetailsNCT07517003
Dermatitis, Dermatitis, Contact
Midyat, Mardin, Turkey (Türkiye)
View Trial DetailsNCT07479004
Dermatitis, Dermatitis, Contact
Banská Bystrica, Slovakia
View Trial DetailsNCT06958003
Dermatitis, Dermatitis, Contact
Cincinnati, Ohio, United States
View Trial Details